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Sa multidisciplinary, multimodality, but minimalist (3M) approach could improve
current outcomes.
Methods: With the addition of a second implanting site within a single Vancouver
program, patients considered high risk for surgery, but relatively low risk for TAVR,
were rigorously screened with functional and cognitive assessments, echocardiog-
raphy, angiography with aortography, and computed tomography (CT). From
a potential pool of 228 accepted transfemoral patients between August 2011 and April
2013, 52 patients underwent SAPIEN XT (Edwards Lifesciences Inc., CA, USA)
valve implantation utilizing percutaneous arterial access. Area based CT sizing, with
balloon under ﬁlling when appropriate, was utilized. The ﬁnal 17 cases were per-
formed without intubation or sedation. Thirty day outcomes are reported according to
the VARC-2 guidelines.
Results: The mean patient age was 83  7 years with a mean STS score of 8.6 
3.7%. Mortality at 30 days was 1.9% (1/52). The median LOS was 1 day (1, 9) with
a mean LOS of 1.8 days. Thirty two patients (62%) were discharged one day post
TAVR. Aortic valve area increased from 0.67  0.14 cm2 to 1.70  0.28 cm2
(p<0.001) and the mean gradient decreased from 43  17 mmHg to 9  3 mmHg (p
< 0.001) at 30 days. Two patients (3.8%) were re-admitted within the ﬁrst 30 days:
one patient underwent elective pacemaker implantation for pre-existing type 2 AV
block on day 7 and one patient with advanced ﬁbrotic lung disease was readmitted
with worsening respiratory symptoms on day 15. At 30 days, there were no major
vascular complications or strokes and 98% (50/51) were NYHA class I or II with mild
or less paravalvular regurgitation.
Conclusions: Rigorous patient screening and improvements in procedural guidance
and device selection permits safe next day discharge in high risk patients. The 3M
approach may help facilitate TAVR in a broader range of lower risk patients.
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Background: Transcatheter aortic valve implantation (TAVI) has been designed to
treat elderly patients with severe aortic stenosis at high risk for surgery. The safety and
effectiveness of TAVI have been demonstrated in numerous studies. The self-
expanding CoreValve prosthesis is implanted retrogradely with vascular access
usually via the femoral or subclavian arteries. However, in certain patients these
access routes are either not possible or are deemed to carry a high risk of vascular
injury. The aim of this report is to describe the European experience use of a direct
aortic approach (DAA) for TAVI in a high risk population and evaluate the impact of
any potential learning curve.
Methods: This multi-centre experience comprises patients treated in the 18 centres in
9 countries in Europe and in Israel, a standard dataset was circulated. between center.
Results: A total of 402 cases have been collected, mean age 81,26.4 years, 54%
male, mean logistic EuroSCORE 25.816.1. 86% of patients were in NYHA func-
tional class  III. Peripheral vascular disease was present in 73% of cases. 58 % of
patients had coronary artery disease and 22% of the patients had undergone previous
coronary artery bypass surgery. The procedure was performed in 130 of cases through
a right anterior mini-thoracotomy in the 2nd intercostal space and via an upper hemi-
sternotomy in the others. A size 29mmCoreValve was implanted in 171 patients.
Procedural success was achieved in 96% of cases. There were two procedural deaths
and 30 day mortality was 9%. The incidence of stroke was 2% and 56 patients (13.9%)
required a new permanent pacemaker. Median post-operative hospitalization was 8
days.
Conclusions: Direct aortic access is a feasible approach for TAVI with the self-
expanding CoreValve prosthesis. These initial and provisional results with this tech-
nique are encouraging given the high risk patient cohort (with a particularly high
incidence of concomitant vascular disease) and the fact that this series includes each
unit's initial experienceJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-120
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Background: An increased incidence of conduction disturbances requiring permanent
pacemaker implantation has been reported with some devices following transcatheter
aortic valve replacement (TAVR). The repositionable and fully retrievable Lotus
Aortic Valve Replacement System (Boston Scientiﬁc, Natick, MA) is being evaluated
in the REPRISE II study. This analysis will evaluate the incidence and predictors of
the need for a permanent pacemaker following implantation of the Lotus Valve.
Methods: REPRISE II is a prospective, single arm, multicenter study of symptomatic
patients with calciﬁed aortic valve stenosis and an aortic annulus of 19-27mmwho were
at high risk for surgery. A total of 120 patients were enrolled and implanted with
a transfemoral 23mm or 27mm Lotus Valve. The primary device performance endpoint
is the mean aortic valve pressure gradient at 30 days post implant, and the primary safety
endpoint is all-cause mortality at 30 days. Echocardiography, CT, and EKG data were
evaluated by independent core labs; results including univariate and multivariate
predictors of need for a pacemaker will be available by the time of presentation.
Results: In a prespeciﬁed interim analysis conducted on the ﬁrst 60 patients, mean age
was 85.5 years, 63% were female, 75% were NHYA Class III/IV at baseline, and mean
STS score was 6.43.0%. Thirty-day follow-up data were available for 58 patients (1
patient withdrew consent and 1 died). In this analysis, 17/58 (29.3%) patients required
a newly implanted pacemaker: 15 for 3rd degreeAVblock, 1 for 1st degreeAVblockwith
right bundle branch block (RBBB) and left anterior fascicular block, and 1 for AF with
slowventricular rate.Of these, 7 (41.2%) had baselinePR interval prolongation, 4 (23.5%)
had baseline RBBB, and 10 (58.8%) had new conduction disturbances immediately after
valvuloplasty. Eleven of the 17 patients (64.7%) still had a paced rhythm at 30 days.
Conclusions: The incidence and predictors of the need for a permanent pacemaker
post-implantation for the full 120-patient cohort in REPRISE II will be available for
the ﬁrst time at TCT 2013.
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Background: The 24 mm sized Colibri TAVI valve is pre-mounted and compressed
upon its delivery balloon catheter at manufacture and is packaged within a 14 French
introducer, sterilized and ready for use into the patient. We report the results and early
clinical follow-up of the ﬁrst human implantation of the Colibri Heart Valve pre-
mounted, pre-packaged TAVI valve in an initial feasibility study.
Methods: An elderly, frail, hypertensive, bedbound female patient with minimal
effort dyspnea and recurrent syncope (functional class 4) was referred for treatment.
Echo-Doppler showed severe aortic stenosis with peak gradient ¼ 154 mmHg (mean
89 mmHg), aortic valve area (AVA) ¼ 0.7 cm2 and preserved left ventricular ejection
fraction of 60%. Surgical valve replacement was not available to her. The minimum
diameter of the femoral arteries was approximately 5.0 mm, precluding transfemoral
approach with available TAVI systems. The local institutional ethics board approved
the procedure as a humanitarian application.
Results: The Colibri valve was implanted in the cardiac catheterization laboratory by
transfemoral approach. Mean aortic gradient decreased to 12 mmHg and AVA
increased to 2.3 cm2 with mild paravalvular leak (PVL). The patient experienced
symptomatic relief. Follow-up echocardiogram performed at 7 days showed trace PVL
and transvalvular mean gradient of 12 mmHg. At 6-month follow-up she is NYHA
Class 1 and echocardiogram showed no aortic insufﬁciency/PVL, mean gradient of 9
mmHg and AVA of 2.3 cm2.
Conclusions: Transfemoral implant of theColibri ready for use transcatheter aortic valve
in its 14 Fr delivery sheath is feasible and efﬁcient. Clinical outcomes at 6 months after
implantation showed sustained beneﬁts suggesting that the Colibri TAVI technology can
enable the successful transfemoral treatment of patients with small femoral arteries.acts/ORAL/TAVR - Outcomes B39
